You are here:

vildagliptin (Galvus)

Advice

Following a full submission:

vildagliptin (Galvus) is accepted for restricted use within NHS Scotland.

Indication under review: treatment of type 2 diabetes mellitus in adults as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.

SMC restriction: for use in patients for whom both metformin and sulphonylureas are inappropriate due to contraindications or intolerance.

In two comparator controlled studies the non-inferiority of vildagliptin to first-line oral anti-diabetic agents was not shown. A network meta-analysis demonstrated similar reductions in HbA1c at 24 weeks for vildagliptin versus another dipeptidyl peptidase 4 (DPP-4) inhibitor.

Drug Details

Drug Name: vildagliptin (Galvus)
SMC Drug ID: 826/12
Manufacturer: Novartis Pharmaceuticals UK Ltd
Indication: As monotherapy, in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.
BNF Category:
Sub Category: 6.1 Drugs used in diabetes
Submission Type: Full submission
Status: Restricted
Date Advice Published: 14 January 2013

Back